Lupin to launch nearly 30 products in US market in FY18 Industry-The Economic Times — June 24, 2018 comments off The drug firm is banking on the introduction of complex generics and biosimilars in the US to maintain its top five position in the market.
The drug firm is banking on the introduction of complex generics and biosimilars in the US to maintain its top five position in the market.